Molecular Partners AG AI Stock Analysis
Want to see CH:MOLN full AI Analyst Report?
Molecular Partners AG (MOLN) AI Stock Analysis
Molecular Partners AG
(Six Swiss:MOLN)
The score is primarily held down by weak financial performance—near-zero recent revenue, recurring losses, and sustained negative operating/free cash flow—despite low leverage. Technicals also detract, with the price below key moving averages and bearish momentum indicators. Valuation is not a clear positive because the negative P/E reflects ongoing losses and there is no dividend support.
Molecular Partners AG (MOLN) vs. iShares MSCI Switzerland ETF (EWL)
- Market Cap
- CHF 153.72M
- Dividend Yield
- ―
- Average Volume (3M)
- 20.86K
- Price to Earnings (P/E)
- -1.8
- Beta (1Y)
- 0.57
- Revenue Growth
- ―
- EPS Growth
- 16.86%
- Country
- Switzerland
- Employees
- 134
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Molecular Partners AG Business Overview & Revenue Model
Company Description
Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market novel therapeutic proteins. Leveraging its proprietary DARPin® platform, the company is advancing a diverse pipeline of prod...
How the Company Makes Money
Molecular Partners primarily makes money through (1) collaboration and licensing arrangements and (2) to the extent applicable, potential downstream commercialization economics tied to partnered or out-licensed programs. Under typical biotech partner...
Molecular Partners AG Earnings Call Summary
Molecular Partners demonstrated significant progress in advancing their pipeline, particularly with the radio DARPin franchise and T cell engager 533, while maintaining a strong financial position. However, the discontinuation of the Novartis collaboration and resulting revenue impact were notable drawbacks.
Q4-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the Molecular Partners Fourth Quarter and Full Year 2024 Results Call, several notable metrics and guidance were provided. For the fiscal year 2024, the company reported revenues of CHF 5 million, exclusively from the Novartis collaboration. Operating expenses were CHF 66 million, within the guidance range of CHF 65 million to CHF 70 million, with 74% allocated to R&D. The net financial result benefited from high interest rates, contributing to an end-of-year cash balance of CHF 149 million, down from CHF 187 million the previous year, resulting in a cash burn of CHF 54 million. Looking ahead to 2025, Molecular Partners anticipates operating expenses between CHF 55 million and CHF 65 million, excluding potential partnership payments. The company is focused on advancing its radio DARPin programs, particularly MP0712, with expectations to start clinical trials and provide initial imaging data by the end of the year, while also progressing with its T cell engager program, MP0533, in AML, with new dosing amendments and outcomes expected by year-end.
Molecular Partners AG Financial Statement Overview
Summary
Financials are very weak overall: revenue fell from 189.6M (2022) to near-zero by 2025/TTM, with sizable recurring net losses (~-51M to -62M). Cash flow remains deeply negative (operating and free cash flow roughly -46M to -92M), indicating continued funding dependence. The main offset is low leverage (debt-to-equity ~0.05 TTM), but the equity/asset base has shrunk materially, signaling runway pressure.
Income Statement
18Very NegativeBalance Sheet
54NeutralCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 4.97M | 7.04M | 189.56M | 9.33M |
| Gross Profit | -1.98M | -2.15M | -42.53M | -40.81M | 138.81M | -46.39M |
| EBITDA | -49.09M | -53.29M | -51.63M | -59.52M | 119.00M | -60.66M |
| Net Income | -51.11M | -61.65M | -54.04M | -61.98M | 117.85M | -63.78M |
Balance Sheet | ||||||
| Total Assets | 64.52M | 102.11M | 158.53M | 198.35M | 262.26M | 172.67M |
| Cash, Cash Equivalents and Short-Term Investments | 57.49M | 93.06M | 149.44M | 186.89M | 249.14M | 132.81M |
| Total Debt | 2.74M | 3.64M | 2.44M | 3.65M | 4.85M | 6.04M |
| Total Liabilities | 13.85M | 21.77M | 16.89M | 21.92M | 27.09M | 65.38M |
| Stockholders Equity | 50.66M | 80.33M | 141.64M | 176.43M | 235.17M | 107.29M |
Cash Flow | ||||||
| Free Cash Flow | -46.20M | -50.24M | -59.97M | -59.81M | 117.15M | -92.26M |
| Operating Cash Flow | -46.04M | -49.53M | -59.25M | -59.01M | 118.57M | -90.95M |
| Investing Cash Flow | 21.80M | 70.82M | 40.49M | 44.64M | -101.12M | -22.24M |
| Financing Cash Flow | -1.10M | -1.15M | 14.43M | -1.17M | -1.57M | 50.58M |
Molecular Partners AG Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:MOLN, the sentiment is Negative. The current price of 2.48 is below the 20-day moving average (MA) of 2.85, below the 50-day MA of 3.13, and below the 200-day MA of 3.28, indicating a bearish trend. The MACD of -0.19 indicates Positive momentum. The RSI at 20.52 is Positive, neither overbought nor oversold. The STOCH value of 14.91 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:MOLN.
Molecular Partners AG Risk Analysis
Molecular Partners AG disclosed 102 risk factors in its most recent earnings report. Molecular Partners AG reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
2 New RisksMolecular Partners AG Peers Comparison
Overall Rating
CH:BSLN81Outperform
CH:SANN52Neutral
CH:IDIA45Neutral
CH:NWRN45Neutral- CH:MOLN44Neutral
CH:MMTX41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| CH:BSLN | 81Outperform | CHF 874.04M | 16.81 | ― | ― | 4.74% | -28.96% |
| CH:SANN | 52Neutral | CHF 227.34M | -6.62 | 354.99% | ― | 107.08% | 55.54% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| CH:IDIA | 45Neutral | CHF 1.08B | -3.56 | ― | ― | -5.32% | -95.96% |
| CH:NWRN | 45Neutral | CHF 191.15M | -6.62 | 258.11% | ― | -82.88% | -212.48% |
| CH:MOLN | 44Neutral | CHF 101.34M | -1.84 | -79.25% | ― | ― | 16.86% |
| CH:MMTX | 41Neutral | CHF 26.60M | -2.13 | -49.18% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CH:MOLN | Molecular Partners | 2.48 | -0.92 | -27.06% | |
| CH:BSLN | Basilea Pharmaceutica | 71.60 | 24.75 | 52.83% | |
| CH:IDIA | Idorsia Ltd | 3.95 | 0.75 | 23.44% | |
| CH:NWRN | Newron Pharmaceuticals SpA | 8.92 | -6.20 | -41.01% | |
| CH:SANN | Santhera Pharmaceuticals Holding Ag | 15.10 | 4.50 | 42.45% | |
| CH:MMTX | MindMaze Therapeutics Holding SA | 0.14 | -2.78 | -95.23% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026